About Menarini Stemline Deutschland GmbH
BPDCN – blastic plasmacytoid dendritic cell neoplasia – is a rare, aggressive dermatohematologic malignancy.
Menarini Stemline has set itself the task of improving the diagnosis and treatment of rare BPDCN and the patients affected.
Menarini Stemline is a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients.
The Rare Disease Day is an important milestone in the year for our awareness work for the BPDCN.